The emergence and spread of chloroquine resistance (CQR) in Plasmodium falciparum has compounded the global problem of malaria, with significant increases in malaria mortality reported in Africa. Our prior grant addressed the hypothesis that pfcrt, which encodes a digestive vacuole (DV) transmembrane protein, was the primary parasite determinant of CQR. This was confirmed by transaction experiments that exchanged mutant and wild type pfcrt alleles, causing a complete phenotypic change in CQ response. Studies have also revealed extraordinary region-specific allelic diversity, implicated pfcrt alleles in resistance to multiple antimalarials, and suggested that mutant pfcrt gametocytes are preferentially transmitted to the mosquito host. Here, we will test whether mutant pfcrt alleles can confer resistance to multiple drugs, define their impact on parasite transmission, and leverage our isogenic pfcrt-modified lines to probe the CQR mechanism and identify functional properties that distinguish mutant and wild type pfcrt.
Specific Aim 1 will test the hypothesis that the global diversity of pfcrt alleles reflects their key role in mediating resistance to CQ and other drugs used regionally to treat CQ-resistant malaria. This will be achieved using allelic exchange techniques to engineer parasites expressing geographically diverse pfcrt alleles with selected mutations, followed by phenotypic characterization of isogenic lines. These experiments benefit from our development of a highly improved transfection system that uses mycobacteriophage integrase to mediate rapid site-specific allelic exchange in P. falciparum.
Specific Aim 2 will test the hypothesis that the enhanced gametocyte production and transmissibility frequently observed with CQ-resistant infections is imparted by mutant pfcrt. Isogenic, pfcrt-modified CQ-resistant and CQ- sensitive clones will be quantitatively assayed for gametocyte development, gamete exflagellation, transmission and oocyst production in infected mosquitoes in the presence or absence of CQ.
Specific Aim 3 will implement biochemical assays to test the hypothesis that CQR is primarily attributable to energy- dependent active CQ efflux that is conferred by PfCRT mutations. These studies will also assess models of passive drug leak and altered DV pH. Using isogenic pfcrt -modified and control lines harboring distinct CQ phenotypes, we propose experiments that will clarify key mechanistic features of pfcrf-mediated CQR and relate this to functional differences between pfcrt alleles and individual polymorphisms. These studies are designed to elucidate the contribution of mutant pfcrt to multidrug resistance, generate novel insights into the transmission and spread of resistance, and identify key functional properties of mutant pfcrt alleles and the CQR mechanism. The results should be of significant benefit to public health programs aimed at identifying and combating drug-resistant malaria.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI050234-09
Application #
7656639
Study Section
Special Emphasis Panel (ZRG1-DDR-N (01))
Program Officer
Rogers, Martin J
Project Start
2001-08-01
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
9
Fiscal Year
2009
Total Cost
$379,083
Indirect Cost
Name
Columbia University (N.Y.)
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Cowell, Annie N; Istvan, Eva S; Lukens, Amanda K et al. (2018) Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science 359:191-199
Ross, Leila S; Dhingra, Satish K; Mok, Sachel et al. (2018) Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun 9:3314
Schuh, Anna Katharina; Rahbari, Mahsa; Heimsch, Kim C et al. (2018) Stable Integration and Comparison of hGrx1-roGFP2 and sfroGFP2 Redox Probes in the Malaria Parasite Plasmodium falciparum. ACS Infect Dis 4:1601-1612
Lee, Andrew H; Dhingra, Satish K; Lewis, Ian A et al. (2018) Evidence for Regulation of Hemoglobin Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine Resistance Transporter. Sci Rep 8:13578
Agrawal, Sonia; Moser, Kara A; Morton, Lindsay et al. (2017) Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. J Infect Dis 216:468-476
Vanaerschot, Manu; Lucantoni, Leonardo; Li, Tao et al. (2017) Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. Nat Microbiol 2:1403-1414
Rahbari, Mahsa; Rahlfs, Stefan; Przyborski, Jude M et al. (2017) Hydrogen peroxide dynamics in subcellular compartments of malaria parasites using genetically encoded redox probes. Sci Rep 7:10449
Blasco, Benjamin; Leroy, Didier; Fidock, David A (2017) Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med 23:917-928
Dhingra, Satish K; Redhi, Devasha; Combrinck, Jill M et al. (2017) A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine. MBio 8:
Gabryszewski, Stanislaw J; Dhingra, Satish K; Combrinck, Jill M et al. (2016) Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLoS Pathog 12:e1005976

Showing the most recent 10 out of 51 publications